Live Accenture Plc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about

Most recent public disclosures: AI-powered summaries of the latest corporate filings

15826
1
Synergy CHC Corp. Synergy CHC Corp. Reports Q2 2025 Revenue of $8.1 Million, Net Income Increases to $1.5 Million

Via official filing (AI summary) | 10 months ago | 0 comments

15827
1
Sow Good Inc. Sow Good Inc. Reports 88% Revenue Decline and Gross Loss in Latest Quarter

Via official filing (AI summary) | 10 months ago | 0 comments

15828
1
Clene Inc. Clene Inc. Reports 70% Revenue Decline in Q2 2025, Plans for Funding Options

Via official filing (AI summary) | 10 months ago | 0 comments

15829
1
LION COPPER & GOLD CORP. Lion Copper and Gold Corp. Reports $4 Million Net Loss for First Half of 2025

Via official filing (AI summary) | 10 months ago | 0 comments

15830
1
Cocrystal Pharma, Inc. Cocrystal Pharma Reports $2.1 Million Net Loss in Q2 2025, Significant Reduction in Operating Expenses

Via official filing (AI summary) | 10 months ago | 0 comments

15831
1
PALVELLA THERAPEUTICS, INC. Palvella Therapeutics Reports $9.5 Million Net Loss in Q2 2025 Amid Increased R&D Expenses

Via official filing (AI summary) | 10 months ago | 0 comments

15832
1
GBT Technologies Inc. GBT Technologies Inc. Reports $215,554 Net Loss and Faces Financial Challenges in Latest 10-Q

Via official filing (AI summary) | 10 months ago | 0 comments

15833
1
Volato Group, Inc. Volato Group Reports $24.9 Million Revenue and $3.6 Million Net Income in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

15834
1
BRAINSTORM CELL THERAPEUTICS INC. Brainstorm Cell Therapeutics Reports Q2 2025 Financial Results with Improved Net Loss

Via official filing (AI summary) | 10 months ago | 0 comments

15835
1
GALECTIN THERAPEUTICS INC Galectin Therapeutics Reports Reduced Net Loss and Advances Clinical Trials in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

15836
1
Lexeo Therapeutics, Inc. Lexeo Therapeutics Reports $26.1 Million Net Loss in Q2 2025, Highlights Clinical Advancements

Via official filing (AI summary) | 10 months ago | 0 comments

15837
1
Onconetix, Inc. Onconetix Reports 84.9% Revenue Decline and $2.4 Million Net Loss in Latest Quarter

Via official filing (AI summary) | 10 months ago | 0 comments

15838
1
Advanced Flower Capital Inc. Advanced Flower Capital Inc. Reports $13.2 Million Net Loss and Strategic Expansion Plans

Via official filing (AI summary) | 10 months ago | 0 comments

15839
1
ABEONA THERAPEUTICS INC. Abeona Therapeutics Reports $400,000 Revenue and $108.8 Million Net Income for Quarter Ending June 30, 2025

Via official filing (AI summary) | 10 months ago | 0 comments

15840
1
Falcon's Beyond Global, Inc. Falcon's Beyond Reports 42% Revenue Growth and $25.11M Net Income in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

15841
1
Prelude Therapeutics Inc Prelude Therapeutics Reports $31.2 Million Net Loss in Q2 2025, Seeks Additional Funding

Via official filing (AI summary) | 10 months ago | 0 comments

15842
1
BK Technologies Corp BK Technologies Reports Revenue Growth and Increased Profitability in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

15843
1
McGraw Hill, Inc. McGraw Hill Reports $535.7 Million Revenue and Net Income Recovery in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

15844
1
ACUREN CORP Acuren Corporation Reports Q2 2025 Revenue Growth Despite Net Loss

Via official filing (AI summary) | 10 months ago | 0 comments

15845
1
Chicago Atlantic BDC, Inc. Chicago Atlantic BDC Reports Significant Growth in Investment Income and Assets for Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

15846
1
Werewolf Therapeutics, Inc. Werewolf Therapeutics Reports $17.98 Million Net Loss in Q2 2025, No Revenue Generated

Via official filing (AI summary) | 10 months ago | 0 comments

15847
1
ROCKWELL MEDICAL, INC. Rockwell Medical Reports 38% Decline in Q2 2025 Net Sales, Net Loss of $3 Million

Via official filing (AI summary) | 10 months ago | 0 comments

15848
1
Protalix BioTherapeutics, Inc. Protalix BioTherapeutics Reports 49% Revenue Growth and Improved Net Loss in Latest 10-Q Filing

Via official filing (AI summary) | 10 months ago | 0 comments

15849
1
Cellectar Biosciences, Inc. Cellectar Biosciences Reports Reduced Losses and Strategic Focus on Cancer Therapies

Via official filing (AI summary) | 10 months ago | 0 comments

15850
1
BIOTRICITY INC. Biotricity Reports 21% Revenue Growth and First Positive Operating Profit

Via official filing (AI summary) | 10 months ago | 0 comments